DrugBiological
GSK1070806 clinical trials
Also written GSK1070806.
- studies test it
- 11
- open now
- 2
- in phase 3
- 0
- first study started
- 2010
Keep track of what changes. Save the GSK1070806 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
11 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 2
GlaxoSmithKline (9) · University of Birmingham (1) · Cambridge University Hospitals NHS Foundation Trust (1)
Studies
Open first, then newest update. How each study uses GSK1070806 is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative ColitisNot yet recruitingPhase 1GlaxoSmithKlineNCT07747480Written as Aletekitug
- A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative ColitisNot yet recruitingPhase 1GlaxoSmithKlineNCT07747467Written as Aletekitug (GSK1070806)
- Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.TerminatedPhase 2GlaxoSmithKlineNCT06447506Written as GSK1070806
- A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic DermatitisTerminatedPhase 2GlaxoSmithKlineNCT05999799Written as GSK1070806
- Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic DermatitisCompletedPhase 1GlaxoSmithKlineNCT04975438Written as GSK1070806
- A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age InclusiveCompletedPhase 1GlaxoSmithKlineNCT05590338Written as GSK1070806
- A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's DiseaseCompletedPhase 1/2University of BirminghamNCT03681067Written as GSK1070806
- Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal TransplantationTerminatedPhase 2GlaxoSmithKlineNCT02723786Written as GSK1070806
- Anti IL-18 (GSK1070806) in Behcet's DiseaseStatus unknownPhase 2Cambridge University Hospitals NHS Foundation TrustNCT03522662Written as GSK1070806
- First Time in Human Study of Intravenous Interleukin-18 AntibodyCompletedPhase 1GlaxoSmithKlineNCT01035645Written as GSK1070806
- Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DMCompletedPhase 2GlaxoSmithKlineNCT01648153Written as GSK1070806
Codes
What other systems call GSK1070806 · ClinicalTrials.gg INT000472
- MeSH (NLM) C000608195GSK1070806One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000608195 | GSK1070806 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.